In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone

Blood

Volumn 103, Issue 3, 2004, Pages 897-902

  Nassar, Taher ^b   Akkawi, Sa'ed ^b   Shina, Ahuva ^b   Haj Yehia, Abdullah ^b   Bdeir, Khalil ^b   Tarshis, Mark ^b   Heyman, Samuel N ^b   Higazi, Abd Al Roof ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; EPITOPE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PHENYLEPHRINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; BRAIN VASCULAR RESISTANCE; CONTROLLED STUDY; FIBRINOLYSIS; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIA; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR RING; VASOCONSTRICTION;

EID: 1642500375     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1685     Document Type: Article

References (29)

1. Carmeliet P, Schoonjans L, Kieckens L, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994;369:419-424.
2. Bdeir K, Murciano JC, Tomaszewski J, et al. Urokinase mediates fibrinolysis in the pulmonary microvasculature. Blood. 2000;96:1820-1826.
3. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J Biol Chem. 1982;257:2912-2919.
4. Bamathan ES, Kuo A, van der Keyl H, McCrae KM, Cines DB. Binding of tissue type plasminogen activator to human endathelial cells: evidence for two distinct binding sites. J Biol Chem. 1988;263:7792-7799.
5. Mulder M, Kohnert U, Fischer S, van Hinsbergh V, Verheijen J. The interaction of recombinant tissue type plasminogen activator and recombinant plasminogen activator (r-PA/BM 06.022) with human endothelial cells. Blood Coagul Fibrinolysis. 1997;8:124-133.
6. Grobmeyer SR, Kuo A, Orishimo M, Okada SS, Cines DB, Bamathan ES. Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells. J Biol Chem. 1993;268:13291-13300.
7. Orth K, Willnow T, Herz J, Gething M, Sambrook J. Low-density lipoprotein receptor-related protein is necessary for the internalization of both tissue-type plasminogen activator-inhibitor complexes and free tissue-type plasminogen activator. J Biol Chem. 1994;269:21117-21122.
8. 2-macroglobulin receptor/low density lipoprotein receptor-related protein: evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J Biol Chem. 1994;269:25668-25676.
9. Wang Y, Tsirka S, Strickland S, Stieg P, Soriano S, Lipton S. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med. 1998;4:228-231.
10. Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation. 1999;99:2440-2444.
11. Cipolla M, Lessov N, Clark W. Postischemic attenuation of cerebral artery reactivity is increased in the presence of tissue plasminogen activator. Stroke. 2000;31:940-945.
12. Zhang L, Strickland DK, Cines DB, Higazi AA-R. Regulation of single chain urokinase binding, internalization and degradation by a plasminogen activator inhibitor 1-derived peptide. J Biol Chem. 1997.
13. Haj-Yehia A, Nassar T, Sachais B, et al. Uroknase-derived peptides regulate vascular smooth muscle contraction i vitro and in vivio. FASEB J. 2000;14:1411-1422.
14. Nassar T, Akkawi Se, Bar-Shavit R, et al. Human α-defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Blood. 2002;100:4026-4032.
15. Nassar T, Haj-Yehia A, Akkawi Se, et al. Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem. 2002;277:40499-40504.
16. Oyama Y, Kawasaki H, Hattori Y, Kanno M. Attenuation of endothelium-dependent relaxation in aorta from diabetic rats. Eur J Pharmacol. 1986;132:75-78.
17. Heyman SN, Goldfarb M, Shina A, Karmeli F, Rosen S. N-acetylcysteine (NAC) ameliorates renal microcirculation: studies in rats. Kidney Int. 2003;63:634-641.
18. Higazi AA-R, Upson R, Cohen R, et al. Interaction of single chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins. Blood. 1996;88:542-551.
19. Keyt B, Paoni N, Refino C, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994;91:3670-3674.
20. Stewart J, Fredenburgh J, Leslie B, et al. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator. J Biol Chem. 2000;275:10112-10120.
21. Chapman D, Lyden P, Lapchak P, Nunez S, Thibodeaux H, Zivin J. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke. 2001;32:748-752.
22. Davydov L, Cheng W. Tenecteplase: a review. Clin Ther. 2001;23:982-997, discussion 981.
23. Van de Werf F, Barron HV, Armstrong PW, et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J. 2001;24:2253-2261.
24. Madison EL, Goldsmith EJ, Gething M-JH, Sambrook JF, Gerard RD, Restoration of serine protease-inhibitor interaction by protein engineering. J Biol Chem. 1990;265:21423-21426.
25. Nassar T, Haj-Yehia A, Akkawi S, et al. Binding of urokinase at low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem. 2002;277:40499-40504.
26. Collen D, Stassen JM, Yasuda T, et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost. 1994;72:98-104.
27. Madison EL, Goldsmith EJ, Gerard RD, Gething MJH, Sambrook JF, Bassel-Duby RS. Amino acid residues that affect interaction of tissue plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A. 1990;87:3530-3534.
28. Kuiper J, Otter M, Voorschuur A, van Zonneveld A, Rijken D, van Berkel T. Characterization of the interaction of a complex of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 with rat liver cells. Thromb Haemost. 1995;74:1298-1304.
29. Bacskai B, Xia M, Strickland D, Rebeck G, Hyman B. The endocytic receptor protein LRP also mediates neuronal calcium signaling via N-methyl-D-aspartate receptors. PNAS. 2000;97:11551-11556.